Isofol Medical AB (publ)

Stockholm Stock Exchange:ISOFOL.ST

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

Sweden

Market Cap

USD 18.63 M

Share Price

USD 0.10

Avg Daily Volume

576,965

Change (1 day)

-3.79%

Change (1 year)

52.68%

Change (YTD)

-49.43%

Isofol Medical AB (publ) Revenue for the year ending December 31, 2024: USD 0.00

Isofol Medical AB (publ) Revenue is USD 0.00 for the year ending December 31, 2024, a -100.00% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Isofol Medical AB (publ) Revenue for the year ending December 31, 2023 was USD 71.16 K, a -94.18% change year over year.
Isofol Medical AB (publ) Revenue for the year ending December 31, 2022 was USD 1.22 M, a -50.46% change year over year.
Isofol Medical AB (publ) Revenue for the year ending December 31, 2021 was USD 2.47 M, a -45.16% change year over year.
Isofol Medical AB (publ) Revenue for the year ending December 31, 2020 was USD 4.50 M.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

Stockholm Stock Exchange: ISOFOL.ST

Isofol Medical AB (publ)

CEO	Mr. Petter Segelman Lindqvist
IPO Date	April 4, 2017
Location	Sweden
Headquarters	Biotech Center
Employees	5
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology

Description

Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.